Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Abaloparatide vs. Alendronate for Osteoporosis

Lara C. Pullen, PhD  |  Issue: September 2020  |  August 10, 2020

Next, the researchers performed a sensitivity analysis that included all participants enrolled in ACTIVE, even those not enrolled in ACTIVExtend. They found a vertebral fracture rate of 3.15 per 100 patient-years among patients who received placebo during ACTIVE and a fracture rate of 1.66 per 100 patient-years among patients who received alendronate in the placebo/alendronate arm of ACTIVExtend. From this finding, the investigators calculated a 1.48 per 100 patient-years reduction after transition from placebo to alendronate.

The reduction in vertebral fractures in the alendronate group was similar to that seen in previous studies examining the effect of alendronate treatment on postmenopausal women with osteoporosis. The investigators saw no differences in the rates of nonvertebral fractures and clinical fractures.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

References

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs. placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial. JAMA. 2016 Aug 16;316(7):722–773.
  2. Bone HG, Cosman F, Miller PD, et al. ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018 Aug 1;103(8):2949–2957.
  3. Leder BZ, Mitlak B, Hu MY, et al. Effect of abaloparatide vs. alendronate on fracture risk reduction in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2020 Mar 1;105(3):938–943.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:abaloparatidealendronateFracturesOsteoporosisosteoporosis treatments

Related Articles

    Reading Rheum

    March 1, 2007

    Handpicked Reviews of Contemporary Literature

    Build Up Bone

    June 1, 2007

    Current management of osteoporosis

    Osteoporosis Experts Discuss Bisphosphonate Holidays

    November 24, 2020

    ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…

    Unexpected Benefits of Bisphosphonates after Hip Fracture

    February 3, 2012

    Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences